Richard Francis Riedel, MD

Associate Professor of Medicine
Member of the Duke Cancer Institute
Campus mail Dept of Medicine, 25179 Morris Bldg, Durham, NC 27710
Phone (919) 681-8031
Email address richard.riedel@duke.edu

Novel therapies for soft tissue and bone sarcomas

In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 2005 - 2007
  • Fellow in Hematology-Oncology, Medicine, Duke University, 2003 - 2004
  • Resident in Medicine, Medicine, Duke University, 2000 - 2003
  • M.D., Thomas Jefferson University, 2000

Grants

Publications

Scheffler, Matthias, Alessandra Holzem, Anna Kron, Lucia Nogova, Michaela A. Ihle, Cornelia von Levetzow, Jana Fassunke, et al. “Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.” Lung Cancer (Amsterdam, Netherlands) 144 (June 2020): 40–48. https://doi.org/10.1016/j.lungcan.2020.04.020.

PMID
32361034
Full Text

Chawla, Sant P., Sanjay Goel, Warren Chow, Fadi Braiteh, Arun S. Singh, Juneko E. Grilley Olson, Atsushi Osada, Iulian Bobe, and Richard F. Riedel. “A Phase 1b Dose-Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma.” Clin Cancer Res, May 7, 2020. https://doi.org/10.1158/1078-0432.CCR-20-0591.

PMID
32381487
Full Text

Keung, Emily Z., Melissa Burgess, Ruth Salazar, Edwin R. Parra, Jaime Rodrigues-Canales, Vanessa Bolejack, Brian A. Van Tine, et al. “Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.” Clin Cancer Res 26, no. 6 (March 15, 2020): 1258–66. https://doi.org/10.1158/1078-0432.CCR-19-1824.

PMID
31900276
Full Text

Haddox, Candace L., and Richard F. Riedel. “Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology.” Expert Rev Anticancer Ther 20, no. 1 (January 2020): 5–8. https://doi.org/10.1080/14737140.2020.1708198.

PMID
31859537
Full Text

Davis, Lara E., Vanessa Bolejack, Christopher W. Ryan, Kristen N. Ganjoo, Elizabeth T. Loggers, Sant Chawla, Mark Agulnik, et al. “Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.” J Clin Oncol 37, no. 16 (June 1, 2019): 1424–31. https://doi.org/10.1200/JCO.18.02374.

PMID
31013172
Full Text

Burgess, Melissa Amber, Vanessa Bolejack, Scott Schuetze, Brian Andrew Van Tine, Steven Attia, Richard F. Riedel, James S. Hu, et al. “Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.” In Journal of Clinical Oncology, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.

Scholars@Duke

Chawla, Sant P., Brian Andrew Van Tine, Seth Pollack, Kristen N. Ganjoo, Anthony D. Elias, Richard F. Riedel, Steven Attia, et al. “A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1(+) soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.” In Journal of Clinical Oncology, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.

Scholars@Duke

Wagner, Andrew J., Vinod Ravi, Kristen N. Ganjoo, Brian Andrew Van Tine, Richard F. Riedel, Rashmi Chugh, Lee D. Cranmer, et al. “ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.” In Journal of Clinical Oncology, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.

Scholars@Duke

Nogova, L., F. Malchers, A. Hillmer, S. Merkelbach-Bruse, A. Pinto, C. Woempner, R. Riedel, et al. “FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC.” Ann Oncol 30 Suppl 2 (April 2019): ii67. https://doi.org/10.1093/annonc/mdz063.082.

PMID
32131324
Full Text

Scheffler, M., R. Frank, M. A. Ihle, D. S. Abdulla, S. Koleczko, L. Nogova, A. Holzem, et al. “Impact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 comutations in non-small cell lung cancer (NSCLC).” Ann Oncol 30 Suppl 2 (April 2019): ii55. https://doi.org/10.1093/annonc/mdz063.045.

PMID
32131286
Full Text

Pages